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Influenza A virus RNA synthesis is catalyzed by the
viral polymerase comprised of the PA, PB1, and
PB2 proteins. We show that the host DDX21 RNA
helicase restricts influenza A virus by binding PB1
and inhibiting polymerase assembly, resulting in
reduced viral RNA and protein synthesis. Later
during infection, the viral NS1 protein overcomes
this restriction by binding to DDX21 and displacing
PB1. DDX21 binds to a region of the NS1 N-terminal
domain that also participates in other critical func-
tions. A virus mutant whose NS1 protein is unable
to bind DDX21 exhibits reduced viral protein syn-
thesis at both late and early times of infection, a
phenotype converted to wild-type upon DDX21
knockdown. As sequential interaction of PB1 and
NS1 with DDX21 leads to temporal regulation of viral
gene expression, influenza A virus likely uses the
DDX21-NS1 interaction not only to overcome restric-
tion, but also to regulate the viral life cycle.
INTRODUCTION
Influenza A viruses, which cause an annual highly contagious
respiratory disease in humans, infect many avian and mamma-
lian species and are responsible for periodic human pandemics
that can result in high mortality rates (Wright et al., 2013). The
primary defense against influenza A has been vaccination, but
antiviral drugs also play an important role, particularly in fast-
spreading pandemics (Ferguson et al., 2006). Currently, two
classes of influenza antiviral drugs are available, targeting either
the viral neuraminidase (oseltamivir, zanamivir) or the viral M2 ion
channel protein (amantadine/rimantadine) (Das et al., 2010).
However, most circulating influenza A viruses are resistant to
amantadine/rimantadine (Deyde et al., 2007), and oseltamivir
resistance is developing among influenza A virus strains (Bloom
et al., 2010; Le et al., 2005), highlighting the need for developing
new antivirals. One approach for developing new antivirals is to
identify host proteins that play critical roles in influenza A virus
replication and to target these host proteins and/or their interac-
tions with specific viral proteins.484 Cell Host & Microbe 15, 484–493, April 9, 2014 ª2014 Elsevier InInfluenza A viruses are enveloped negative-strand RNA
viruses that contain 8 genome segments encoding 13 or 14
proteins (Krug and Fodor, 2013; Wise et al., 2012). Replication
of influenza viral RNA (vRNA), which occurs in the nucleus,
is catalyzed by the three polymerase proteins (PA, PB1, and
PB2) in association with the nucleoprotein (NP) (Krug and Fo-
dor, 2013; Resa-Infante et al., 2011). Efficient replication of influ-
enza A virus requires the functions of the NS1 protein, a
nonstructural protein that employs several strategies to inhibit
the host antiviral response and regulates other cell and virus
functions (Krug and Garcia-Sastre, 2013). One important
function of the NS1 protein is the inhibition of host mRNA synthe-
sis by binding a cellular 30 end-processing factor, the 30 kDa
subunit of the cleavage and polyadenylation specificity factor
(CPSF30) (Nemeroff et al., 1998). Interestingly, some of the viral
polymerases in the nucleus are associated with NS1-CPSF30
complexes that were purified by affinity selection of CPSF30
(Kuo and Krug, 2009).
Here, we purify CPSF30-NS1 complexes by sequential affinity
selection of CPS30 and NS1 and identify the associated host
proteins by mass spectrometry. We demonstrate that one of
the associated proteins, the DDX21 RNA helicase, is a host
restriction factor that regulates influenza A virus gene expres-
sion. Our results show that DDX21 suppresses viral RNA syn-
thesis and hence viral protein synthesis at early times after
infection. DDX21 binds the PB1 protein and, as a result, inhibits
assembly of the tripartite viral RNA polymerase. Further, we
show that DDX21-mediated antiviral activity is countered by
the NS1 protein, which binds DDX21 and displaces PB1 from
DDX21. The NS1 protein is comprised of two functional domains
that are connected by a short linker: N-terminal RNA-binding
domain (RBD) (amino acids 1–73), and C-terminal effector
domain (ED) (amino acids 85–end) (Krug and Garcia-Sastre,
2013). We identify the binding site for DDX21 on the NS1 protein,
which is in the RBD, and demonstrate that a recombinant
virus encoding a NS1 protein with a mutated DDX21 binding
site does not counteract endogenous DDX21-induced inhibition
of viral protein synthesis at later times of infection. These
results establish that the NS1 protein is responsible for coun-
tering endogenous DDX21 antiviral activity at later times in
infected cells.
Our results strongly support a mechanism by which the
sequential interaction of PB1 and NS1 with endogenous
DDX21 regulates viral gene expression in infected cells. In this
mechanism, influenza A virus transforms the DDX21 hostc.
Figure 1. Purification of Infected Cell CPSF30-NS1 Complexes from
Influenza A Virus-Infected Cells
(A) Purification procedure.
(B) Immunoblots (IBs) for the viral PA, PB1, PB2, NP, and NS1 proteins and for
CPSF30 in the purified CPSF30-NS1 complexes (Flag-NS1 sample) and in the
control (WT NS1) sample.
(C) Gel electrophoresis, followed by Coomassie blue staining, of the proteins
in the purified CPSF30-NS1 complexes and the control sample. See also
Table S1.
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via the binding of DDX21 by the NS1 protein.
RESULTS
Purification of Infected Cell CPSF30-NS1 Complexes
To purify these infected-cell CPSF30-NS1 complexes, 293T
cells were transfected for 24 hr with a plasmid expressing gluta-
thione S-transferase (GST)-tagged CPSF30 and then infected for
12 hr with 2 plaque-forming units (pfu)/cell of a recombinant influ-
enza A/Udorn/72 (Ud) virus that expresses a NS1 protein with an
N-terminal Flag tag (Figure 1A). As a control, cells were infected
with wild-type (WT) Ud virus that expresses an untagged NS1
protein. The CPSF30-NS1 complexes were purified from in-
fected cell extracts by sequential GST and Flag selections. Im-
munoblots showed that the purified complexes contain the three
polymerase subunits and NP (Figure 1B), confirming our previ-
ous results (Kuo and Krug, 2009). GST-CPSF30 and Flag-NS1
(27 kDa) were also identified, but Flag-tagged NS2/NEP protein
(15 kDa) was not detected, presumably because it does not bind
to CPSF30 and hence was removed by GST selection. The
proteins associated with the purified NS1-CPSF30 complexes
(Flag-NS1 sample) and the control preparation (WT NS1 sample)
were resolved by denaturing gel electrophoresis, followed by
Coomassie blue staining (Figure 1C). The Flag-NS1 sample con-
tains proteins larger than 65 kDa that were largely absent from
the WT NS1 sample. Mass spectrometry of the proteins of 70–
90 kDamolecular weights in the Flag-NS1 sample primarily iden-
tified the viral polymerase and NP proteins. In contrast, massCellspectrometry of the 90–110 kDa molecular proteins identified a
substantial number of peptides of DDX21 (Table S1).
The DDX21 Helicase Inhibits Virus Replication by
Suppressing Viral RNA Synthesis at Early Times after
Infection
To determine whether DDX21 plays a role in influenza A virus
replication, we transfected a DDX21-specific siRNA into HeLa
cells, efficiently knocking down DDX21 (Figure 2A). The knock-
down cells and cells transfected with a control siRNA were
infected with H3N2 influenza A/Udorn/72 (Ud) or H1N1 influenza
A/WSN/33 (WSN) at a low multiplicity of infection (0.001 pfu/cell)
(Figure 2B). Replication of these two influenza A viruses was
substantially enhanced in DDX21 knockdown cells, approxi-
mately 30-fold compared to control cells, demonstrating that
DDX21 inhibits influenza A virus replication. To verify these
results, we used a second siRNA and a different human cell
line, Calu3 cells, which supports robust replication of Ud and
other influenza A viruses (Figure S1 available online). Knockdown
of DDX21 with either siRNA enhanced replication of Ud virus
approximately 10-fold in Calu3 cells, establishing that DDX21
inhibits influenza A virus replication in human cells.
To identify the step(s) at which suppression occurs, DDX21
knockdown and control HeLa cells were infected at a high
multiplicity (2 pfu/cell) with the Ud virus, and the synthesis of viral
proteins was assayed using immunoblots (Figure 2C). The time
course of viral protein production in control cells exhibits the
temporal regulation of gene expression characteristic of influ-
enza A virus replication (Shapiro et al., 1987; Skehel, 1973): early
synthesis of the NS1 protein that increases in the 6–9 hr period of
infection, followed by high-level synthesis of viral structural
proteins, HA (hemagglutinin), NP, and M1 (matrix protein) at
12 hr postinfection. This temporal regulation was largely absent
in the DDX21 knockdown cells. The HA, NP, and M1 proteins
were produced in the DDX21 knockdown cells at substantial
levels during the 6–9 hr time period, greatly exceeding the levels
produced in the control cells. At 12 hr after infection, synthesis
of all the viral proteins in control cells increased substantially,
and as a consequence, the levels of all the viral proteins in the
DDX21 knockdown and control cells were similar. Hence, the
synthesis of late proteins occurred at much earlier times in
the DDX21 knockdown cells, demonstrating that DDX21 delays
the synthesis of these viral proteins. A similar stimulation of the
early synthesis of late viral proteins resulting from DDX21 knock-
down was observed in another human cell line, HEL-299 cells
(Figure S2).
To determine whether DDX21 acts at the level of viral RNA
synthesis, we measured the levels of the mRNAs and vRNAs
that encode two late proteins (M1 and neuraminidase [NA]) using
quantitative RT-PCR (Figure 2D). The levels of these viral RNAs
were substantially higher at early times (at 1–3 hr postinfection)
in the DDX21 knockdown cells, accounting for the increased
early synthesis of late viral proteins in these cells. We conclude
that DDX21 inhibits viral RNA synthesis at early times after infec-
tion and, as a result, delays the onset of the rapid synthesis of
late vRNAs andmRNAs. At 6 hr after infection, the levels of these
mRNAs and vRNAs were similar in knockdown and control cells,
indicating that the inhibition of viral RNA synthesis caused by the
DDX21 protein had largely ceased.Host & Microbe 15, 484–493, April 9, 2014 ª2014 Elsevier Inc. 485
Figure 2. The DDX21 Helicase Inhibits Virus
Replication by Suppressing Viral RNA Syn-
thesis at Early Times of Infection
(A) Efficient knockdown of endogenous DDX21 in
HeLa cells using DDX21-1 siRNA. Cell extracts
were immunoblotted with an antibody (Ab) against
DDX21 (Abcam).
(B) DDX21 inhibits replication of Ud andWSN virus
in HeLa cells. HeLa cells were transfected with
DDX21-1 siRNA or control siRNA for 36 hr, fol-
lowed by infectionwith 0.001 pfu/cell of Ud orWSN
virus. Virus production at the indicated times after
infection was determined by plaque assays in
MDCK cells. The bars show the SD of triplicate
measurements of virus production.
(C) Time course of viral protein synthesis in
HeLa cells treated with DDX21-1 siRNA or control
siRNA. After 36 hr of siRNA treatment, cells were
infected with 2 pfu/cell of Ud virus. Cells collected
at the indicated times after infection were lysed in
RIPA buffer (50 mM Tris-HCl [pH 7.5], 150 mM
NaCl, 1% NP40, 0.5% sodium deoxycholate,
0.1% SDS) plus complete protease inhibitor
(Roche). An aliquot was analyzed by IBs probed
with Abs against the NS1 protein, b-actin (Cell
Signaling), or a goat Ab against themajor structural
proteins of the Ud virus (HA, NP, and M1) provided
by Robert A. Lamb (designated as Ud Ab) (Chen
et al., 2007).
(D) Time course of synthesis of M1 and NAmRNAs
and vRNAs in HeLa cells treated with DDX21
siRNA or control siRNA. Cells were infected with 2
pfu/cell of Ud virus, and total RNA was isolated at
the indicated times after infection using the TRIzol
reagent. The amounts of the mRNAs and vRNAs
were determined by quantitative RT-PCR using
the primers shown in Supplemental Information.
The reactions were carried out in triplicate and
normalized to the levels of b-actin mRNA amplified
with b-actin-specific primers. The numbers on the y axis correspond to the levels of the mRNA or vRNA relative to the level of the mRNA or vRNA at 1 hr
postinfection in cells treated with the control siRNA. The bars show the SD of the triplicate determinations. See also Figures S1 and S2.
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To elucidate the mechanisms of these DDX21-mediated effects
on viral RNA synthesis, we identified the viral protein(s) that bind
DDX21 during infection. Human 293T cells were transfected for
24 hr with a plasmid expressing GST-DDX21 and, as control, a
plasmid expressing GST, followed by infection with 2 pfu/cell
of Ud virus. At 12 hr after infection, cell extracts were GST
selected, followed by immunoblots to detect viral proteins (Fig-
ure 3A). Both the NS1 and PB1 proteins were specifically
selected by GST-DDX21, and these associations were ribonu-
clease A (RNase A)-resistant, demonstrating that both NS1 and
PB1 bind DDX21 in an RNA-independent manner in infected
cells. Binding of DDX21 to the other two polymerase subunits,
PB2 and PA, or to other viral proteins was not detected. To deter-
mine whether DDX21 interacts with the PB1 protein in uninfected
cells, we carried out a cotransfection experiment. As shown in
Figure 3B, Ud PB1 binds DDX21 independently of RNA in
cotransfection assays. In contrast, no detectable binding of
PB2 or PA to DDX21was observed in cotransfection assays (Fig-
ure S3), as is also the case in infected cells (Figure 3A). The PB1
proteins of H1N1 A/WSN/33 (WSN) and H5N1 A/Hong Kong/
483/97 (HK97) influenza A viruses also bind DDX21 in transfec-486 Cell Host & Microbe 15, 484–493, April 9, 2014 ª2014 Elsevier Intion assays (Figure 3B), showing that DDX21 binding is shared
by the PB1 proteins of other influenza A virus strains. As
analyzed by cell fractionation, whereas plasmid-expressed
PB1 protein is localized in the cytoplasm, as shown previously
by others (Fodor and Smith, 2004), cotransfection of PB1 and
DDX21 plasmids results in a significant portion of PB1 entering
the nucleus (Figure S4).
To establish whether DDX21 inhibits viral RNA synthesis via its
binding of PB1, we tested the effect of DDX21 on viral RNA
synthesis as measured in the dual-luciferase minigenome assay,
which was carried out as previously described (Marklund et al.,
2012). Polymerase II-driven pcDNA3 plasmids expressing PB1,
PB2, PA, and NP were cotransfected into 293T cells. The
vRNA template was provided by transfecting a polymerase
I-driven pHH21 plasmid that expresses in the negative sense
the firefly luciferase containing the 50- and 30-terminal regions
of one of the Ud vRNAs. In addition, a polymerase II plasmid
expressing the Renilla luciferase was transfected to correct for
differences in transfection efficiencies. The firefly/Renilla lucif-
erase ratio measures the level of luciferasemRNA synthesis (Fig-
ure 4A). Increasing amounts of a pcDNA3 plasmid expressing
DDX21 inhibited viral RNA synthesis, demonstrating thatc.
Figure 3. Identification of the Viral Proteins
that Bind DDX21
(A) DDX21 binds NS1 and PB1 in infected cells.
293T cells were transfected for 24 hr with a
plasmid expressing GST-DDX21 or GST. The cells
were infected with 2 pfu/cell of Ud virus for 12 hr,
and cell extracts with or without treatment with
10 mg/ml of RNase A for 4 hr were GST selected.
Aliquots of the eluates were immunoblotted using
the indicated Abs. Rabbit Ab against PB1 was
provided by Krister Melen and Ikka Julkunen.
Monoclonal Abs against PA and PB2 were pro-
vided by Juan Ortin (Ochoa et al., 1995).
(B) DDX21 binds the PB1 protein of several influ-
enza A virus strains in uninfected cells. 293T cells
were transfected for 48 hr with a plasmid ex-
pressing the PB1 protein from the indicated influ-
enza A virus strain and a plasmid expressing
GST-DDX21 or GST. Cell extracts were prepared
by treating cells with a buffer containing 50 mM
Tris-HCl (pH 7.5), 100 mMNaCl, 0.5% Nonidet P-40, plus complete protease inhibitor, followed by rotation of the extracts for 30 min at 4C. After clarification by
low-speed centrifugation at 4C, the extracts with and without RNase A treatment (10 mg/ml) were GST selected using glutathionemagnet beads (Pierce), and the
eluates were immunoblotted with PB1 Ab. Also see Figures S3 and S4.
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by directly measuring luciferase mRNA using quantitative RT-
PCR (lower right panel of Figure 4A).
To determine whether the inhibition of viral RNA synthesis by
DDX21 requires its helicase activity as well as its binding of
PB1, we generated a mutant DDX21 protein in which the DEAD
sequence required for helicase activity was changed to AAAD.
This mutant DDX21 protein inhibited viral RNA synthesis as
effectively as WT DDX21 (Figure 4B), demonstrating that inhibi-
tion does not require DDX21 helicase activity and is most likely
solely due to DDX21 binding of PB1. Based on this result, we
then tested whether one of the three major DDX21 domains is
sufficient for inhibiting viral RNA synthesis (Figure S5). This
was not the case: the N-terminal domain, the core helicase
domain, and the C-terminal domain were poorly, if at all, active
in inhibiting viral RNA synthesis.
To determine whether DDX21 inhibits assembly of the viral
polymerase or binds to the formed polymerase complex, we
cotransfected plasmids expressing PB2, PA, and C-TAP-tagged
PB1, followed by TAP selection to determine which polymerase
proteins were associated with PB1 in the absence and presence
of DDX21 (1 mg) (Figure 4C). DDX21, which was TAP selected,
and hence bound to PB1, substantially reduced the amounts
of PB2 and PA that were TAP selected. In the experiment shown
in Figure 4C, the amounts of TAP-selected PB2 and PA were
reduced by approximately 65% and 75%, respectively. The
reductions observed in two other experiments were 60%–70%
and 70%–80% for PB2 and PA, respectively. These results
demonstrate that DDX21, via its binding of PB1, inhibits assem-
bly of the viral polymerase.
The NS1 Protein Binds DDX21 and Displaces PB1 from
DDX21
The Ud NS1 protein, like PB1, binds DDX21 independently of
RNA in cotransfection assays (Figure 5A), demonstrating that
the NS1 protein can bind DDX21 in uninfected cells as well as
in infected cells. To determine whether the NS1 protein com-
petes with the PB1 protein for binding DDX21, we cotransfectedCell1 mg each of plasmids expressing GST-DDX21 and PB1, plus
increasing amounts (0.2–1.0 mg) of a plasmid encoding
33Flag-tagged WSN NS1. The amounts of PB1 and NS1 asso-
ciated with DDX21 were assayed by GST selection of DDX21 fol-
lowed by PB1 and Flag immunoblots, respectively (Figure 5B).
Transfection of 1 mg of theWSNNS1 plasmid led to the displace-
ment of PB1 from DDX21 coupled with the binding of NS1 to
DDX21 (lane 10), demonstrating that NS1 competes with PB1
for binding to DDX21.
DDX21 Binds to the N-Terminal RNA-Binding Domain of
the NS1 Protein
The NS1 protein is comprised of twomajor domains: (1) N-termi-
nal RBD (amino acids 1–73) that binds dsRNA and (2) ED (amino
acids 85–C terminus) (Krug and Garcia-Sastre, 2013). To
determine which of these two NS1 domains bind DDX21, we
expressed the following GST-tagged NS1 regions in bacteria:
amino acids 1–215, representing the full-length protein; amino
acids 1–73, representing the RBD; and amino acids 74–215,
representing the ED. These GST-tagged proteins, and also the
GST tag alone, were affinity selected on glutathione magnetic
beads, which were thenmixed with 293T cell extracts containing
plasmid-expressed Flag-DDX21. After RNase A treatment, the
amount of DDX21 that was bound to the immobilized GST
species on the glutathione beads was assayed using a Flag
immunoblot. As shown in Figure 6A, DDX21 binds the RBD,
but not the ED, of the NS1 protein.
To determine which amino acids in the NS1 RBD are
required for binding DDX21, we first focused on surface-
exposed amino acids in one region of the RBD (R37, R38,
K41, R44) and, as a control, a surface-exposed amino acid in
another region of the RBD (K70) (Figure 6B). We expressed
GST-tagged RBDs in which one of these amino acids was
changed to alanine (A) (Figure 6C). We also expressed a
GST-tagged RBD in which both K41 and R44 were changed
to As. The RBDs containing K41A, R44A, or both K41A and
R44A bound little or no DDX21, and the RBDs containing
R37A or R38A bound only low amounts of DDX21. In contrast,Host & Microbe 15, 484–493, April 9, 2014 ª2014 Elsevier Inc. 487
Figure 4. DDX21 Inhibits Viral RNA Synthe-
sis by Binding PB1 and Inhibiting Formation
of the Viral Polymerase
(A) Effect of DDX21 on viral RNA synthesis
measured in dual-luciferase reporter assays
carried out as described in the text. The firefly/
Renilla luciferase ratio, which measures luciferase
mRNA synthesis, was determined in the absence
and presence of the indicated amounts of the
transfected DDX21 plasmid. The ratios in the
presence of the DDX21 plasmid were normalized
to the ratio in the absence of DDX21. The
assays were carried out in triplicate. The bars
show the SD of the triplicate determinations.
Quantitative RT-PCR was carried out in triplicate
to verify that this ratio accurately reflects the
amount of luciferase mRNA produced (lower
right panel). The firefly mRNA levels in cells
transfected with the DDX21 plasmid were
normalized to the firefly mRNA level in cells
transfected with the empty plasmid (0 mg DDX21).
The bars show the range of the triplicate results.
The levels of the viral proteins in the absence and presence (1 mg) of the DDX21 plasmid weremeasured by IBs to establish that DDX21 did not affect the synthesis
of the viral proteins (lower left panel).
(B) DDX21 lacking helicase activity maintains the ability to inhibit viral RNA synthesis. The DDX21 plasmid (1 mg) that was cotransfected in the luciferase reporter
assay expressed either WT DDX21 or DDX21 in which the DEAD sequence was changed to AAAD.
(C) DDX21 inhibits the formation of the viral polymerase. 293T cells were cotransfected for 48 hr with plasmids expressing TAP-tagged PB1, PA, and PB2 andwith
a plasmid expressing DDX21 or an empty vector (EV). Cell extracts prepared as described in the legend of Figure 2B were TAP selected, and the eluates were
immunoblotted with the indicated Abs. ImageJ software (NIH) was used to quantitate the PB1, PA, and PB2 IBs. p values calculated via a one-tailed Student’s
t test are shown. See also Figure S5.
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the WT RBD. Consequently, we conclude that the region
comprised of R37, R38, K41, and R44 is required for the bind-
ing of the NS1 RBD to DDX21.
To determine whether this region of the RBD is sufficient for
the binding of full-length NS1 protein to DDX21 and displacing
PB1 from DDX21, we cotransfected plasmids expressing
GST-DDX21, PB1, and either WT NS1 protein or a NS1 protein
with K41A and R44A mutations (41/44 NS1 protein). GST-
DDX21 was affinity selected on glutathione magnetic beads,
and the amounts of the PB1 and NS1 protein bound to the im-
mobilized DDX21 after RNase A treatment were assayed by im-
munoblots (Figure 6D). The WT NS1 protein binds DDX21 and
largely displaces PB1 from binding DDX21. In contrast, the 41/
44 NS1 protein does not bind DDX21 and does not displace
PB1 from binding DDX21. We also compared the abilities of
the WT and 41/44 NS1 proteins to reverse DDX21-induced inhi-
bition of viral RNA synthesis as determined using the minige-
nome assay (Figure 6E). The addition of 1 mg of a plasmid
expressing the 41/44 mutant NS1 protein did not relieve
DDX21-induced inhibition of viral RNA synthesis. In contrast,
addition of 1 mg of a plasmid expressing WT NS1 protein
restored approximately 20%–25% of the viral RNA synthesis
observed in the absence of DDX21. Larger amounts of the WT
NS1 plasmid did not increase the extent of restoration of viral
RNA synthesis. Complete restoration of viral RNA synthesis
did not occur, presumably because the NS1 protein inhibits
the activity of one or more components of the viral RNA poly-
merase. For example, the NS1 protein has been shown to
bind NP (Robb et al., 2011), and such binding could inhibit viral
polymerase activity.488 Cell Host & Microbe 15, 484–493, April 9, 2014 ª2014 Elsevier InA Recombinant Influenza A Virus Encoding a 41/44
Mutant NS1 Protein Establishes that the NS1 Protein
Counteracts Endogenous DDX21 Antiviral Activity in
Infected Cells
The region of the NS1 RBD required for binding DDX21 (Fig-
ure 6C) also participates in binding dsRNA, a-importin,
TRIM25, and NP (Cheng et al., 2009; Chien et al., 2004; Gack
et al., 2009; Mele´n et al., 2007; Robb et al., 2011). Consequently,
substitution of any of the amino acids in this RBD region is
expected to affect functions in addition to DDX21 binding. For
this reason, it was not feasible to generate a mutant virus encod-
ing a NS1 protein that is solely defective in binding DDX21 and
inhibiting its antiviral activity. Our approach was to determine
whether we could generate a recombinant virus encoding a
mutant NS1 protein whose defects include an inability to combat
DDX21-mediated inhibition of virus gene expression. We gener-
ated a Ud recombinant virus that expresses a NS1 protein with
both the K41A and R44Amutations (41/44 virus). The 41/44 virus
is attenuated during multiple-cycle growth in human Calu3 cells
(0.001 pfu/cell). It replicates slower than the WT virus, yielding
virus approximately 30-fold less at 30–60 hr after infection (Fig-
ure 7A). The 41/44 virus is also attenuated during single-cycle
growth in Calu3 cells (5 pfu/cell), producing virus approximately
5-fold less than the WT virus at 10 and 12 hr after infection (Fig-
ure 7B). Attenuation of the 41/44 virus could be causedby several
defects of the 41/44 NS1 protein, including not only a defect in
countering DDX21 antiviral activity, but also defects in binding
dsRNA, a-importin, and NP (Cheng et al., 2009; Chien et al.,
2004; Gack et al., 2009; Mele´n et al., 2007; Robb et al., 2011).
To establish that one of the defects of the 41/44 virus stems
from the inability of its NS1 protein to counteract DDX21 antiviralc.
Figure 5. NS1 Protein Binds DDX21 and Displaces PB1 from DDX21
(A) DDX21 binds the NS1 protein in uninfected cells. 293T cells were trans-
fected for 48 hr with a plasmid expressing the Ud NS1 protein and a plasmid
expressing GST-DDX21 or GST. Cell extracts prepared as described in the
legend of Figure 3B, with and without RNase A treatment, were GST selected,
and the eluates were immunoblotted with NS1 Ab.
(B) NS1 displaces PB1 from binding DDX21. 293T cells were transfected for
48 hr with the indicated amounts of plasmids expressing GST-DDX21,
33Flag-WSN NS1, and Ud PB1. Cell extracts treated with RNase A were GST
selected, and the amounts of PB1 and NS1 in the eluates were measured by
IBs probed with PB1 or Flag Ab, respectively.
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cells were infected with 2 pfu/cell of the WT or 41/44 virus, and
the levels of viral proteins at 9 and 12 hr after infection were
determined using immunoblots (Figure 7C). In both WT- and
41/44-infected cells, DDX21 knockdown increased the levels
of viral proteins at 9 hr after infection (lanes 1, 2, 5, and 6), result-
ing from the inhibition of viral RNA synthesis by DDX21 (Fig-
ure 2D). In WT-infected cells at 12 hr after infection, essentially
the same levels of viral proteins were produced in control and
DDX21 knockdown cells (Figure 7C, lanes 3 and 4), indicating
that DDX21-mediated inhibition of viral protein synthesis ceased
between 9 and 12 hr after infection. This was not the case in 41/
44 virus-infected cells: at 12 hr after infection, the levels of viral
proteins in control cells remained substantially lower than the
amounts in DDX21 knockdown cells (Figure 7C, lanes 7 and 8),
indicating that DDX21-mediated inhibition of viral protein synthe-
sis continued from 9 to 12 hr after infection.We conclude that the
WT NS1 protein displaces PB1 from binding endogenous
DDX21, whereas the 41/44 mutant NS1 protein, which does
not bind DDX21, does not displace PB1 from binding DDX21
during infection. Consistent with this conclusion, DDX21 knock-
down increased the replication of the 41/44 virus in Calu3 cells
significantly more than the replication of theWT virus (Figure S6),
showing that the interaction of DDX21 with PB1 is more delete-
rious to the 41/44 virus.
DISCUSSION
A major goal of influenza A virus research is to identify specific
host proteins that play critical roles in virus replication via their in-
teractions with viral proteins. Our current approach for identi-Cellfying such host proteins has been to purify infected cell macro-
molecular complexes that contain the NS1 protein bound to
the cellular CPSF30 30 end-processing factor, and to identify
cellular proteins that are consistently associated with these
complexes. The only proteins that should be present are
CPSF30, NS1, and cellular and viral proteins that CPSF30 and
NS1 interact with, either directly or indirectly (most likely via
specific host proteins). We then determine whether these cellular
proteins have specific functions during influenza A virus infec-
tion. Here, we show that the DDX21 RNA helicase that is associ-
ated with these NS1-CPSF30 complexes is a host factor that
regulates viral RNA synthesis during infection via sequential
interaction with the viral PB1 and NS1 proteins. The binding of
DDX21 to NS1 explains why it is associated with NS1-CPSF30
complexes. Interestingly, DDX21 was not identified in any of
the RNAi-based genome-wide screens for host proteins involved
in influenza A virus replication (Watanabe et al., 2010). In addi-
tion, a recent bioinformatics approach to identify host proteins
that interact with influenza virus proteins did not predict an inter-
action of DDX21with either NS1 or PB1 (de Chassey et al., 2013).
It was reported previously that DDX21 is associated with a PA-
PB1 complex that was generated in uninfected cells using plas-
mids to overexpress these two proteins and that this association
was eliminated by RNase A treatment (Bradel-Tretheway et al.,
2011). Our results clearly show that this is not the case in
virus-infected cells, where DDX21 binds the PB1 protein in the
absence of PA in a RNase A-resistant manner, highlighting the
importance of identifying specific interactions between viral
and host proteins in virus-infected cells.
Many cellular proteins have previously been reported to bind
to the NS1 protein, and some of these interactions with NS1
may be mutually exclusive (Krug and Garcia-Sastre, 2013). In
addition, at least some of the cellular proteins other than
DDX21 that are associated with the purified NS1-CPSF30 com-
plexes (Table S1) may also bind to NS1. It is therefore likely that
there are multiple NS1-CPSF30 complexes that differ with
respect to the cellular protein(s) that are bound to the NS1 pro-
tein. These complexes also probably differ with respect to the
presence of the tripartite viral polymerase with its associated
NP protein. Our results indicate that the NS1-CPSF30 complex
that contains DDX21 most likely does not also contain the viral
polymerase with its associated NP, particularly because
DDX21 binds only the PB1 subunit of the viral polymerase in
infected cells. It is not known how the viral polymerase and its
associated NP are brought into the NS1-CPSF30 complexes.
One possibility is that the reported interaction of NS1 with NP
(Robb et al., 2011) is responsible for bringing the viral polymer-
ase with its associated NP into a NS1-CPSF30 complex. If this
were the case, DDX21 and the viral polymerase with its associ-
ated NP would be in different NS1-CPSF30 complexes because
DDX21 and NP bind to essentially the same site in the NS1 RBD
(Robb et al., 2011; present study). Alternatively, other cellular
proteins that we identified in the purified NS1-CPSF30 com-
plexes could be responsible for bringing the polymerase with
its associated NP into NS1-CPSF30 complexes. It will be of inter-
est to determine whether these other cellular proteins have pre-
viously unidentified roles during influenza A virus infection.
In the present study, we used several approaches to demon-
strate that endogenous DDX21 sequentially interacts with theHost & Microbe 15, 484–493, April 9, 2014 ª2014 Elsevier Inc. 489
Figure 6. Identification of the Amino Acids in the NS1 RBD that Are Required for Binding DDX21
(A) Bacteria-expressed GST and the indicated GST-tagged NS1 proteins were bound to glutathione magnetic beads, which were then incubated in the presence
of RNase A for 4 hr with 293T cell extracts containing plasmid-expressed Flag-DDX21. The proteins eluted from the beads were analyzed by an IB probed with
Flag Ab (top panel) and by Coomassie blue staining (bottom panel).
(B) The structure of the RBD showing the amino acids (R37/R370, R38/R380, K41/K410, R44/R440, K70/K700 ) that were replaced with alanines. The RBD structure
was generated from Protein Data Bank (PBD) ID 1NS1.
(C) Bacteria extracts containing GST, GST-NS1 (1–73), or GST-NS1 (1–73) containing the indicated amino acid substitutions were bound to glutathione magnetic
beads, which were then incubated in the presence of RNase A with 293T containing plasmid-expressed Flag-DDX21. The eluted proteins were analyzed by an IB
probed with Flag Ab and by Coomassie blue staining.
(D) 293T cells were cotransfected for 48 hr with plasmids expressing GST-DDX21, PB1, and either WT or 41/44 NS1 protein. Cell extracts were RNase A treated
and GST selected, and the eluates were immunoblotted with PB1 or Flag Ab.
(E) The dual-luciferase assay for viral RNA synthesis was carried out in triplicate as described in the text. Where indicated, 1 mg of a plasmid expressing DDX21,
and 1 mg of a plasmid expressing either WT or 41/44 NS1 protein, was added. The firefly/Renilla ratio was normalized to the ratio in the absence of DDX21. The
levels of the WT and 41/44 NS1 proteins, DDX21, and b-actin were determined by IBs.
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Figure 7. The NS1 Protein Counteracts
Endogenous DDX21 Antiviral Activity during
Virus Infection
(A) Calu3 cells were infected with 0.001 pfu/cell of
WT or 41/44 virus. Virus production at the indi-
cated times after infection was determined by
plaque assays. The bars show the SD of triplicate
measurements of virus production.
(B) Calu3 cells were infected with 5 pfu/cell of WT
or 41/44 virus. The bars show the SD of triplicate
measurements of virus production.
(C) HeLa cells were transfected with a DDX21
siRNA or a control siRNA for 36 hr, followed by
infection with 2 pfu/cell of WT or 41/44 virus. At 9
and 12 hr after infection, cell extracts were im-
munoblotted with Ud, NS1, or b-actin Ab. See also
Figure S6.
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resulting in the regulation of viral RNA synthesis. DDX21 knock-
down established that endogenous DDX21 inhibits viral RNA
synthesis at early times after infection, even as early as 1–3 hr
after infection (Figure 2D), and a GST pull-down showed that
DDX21 binds PB1 as well as NS1 in infected cells. The interac-
tion of DDX21 with PB1 would be expected to inhibit viral RNA
synthesis, and this expectation was verified by minigenome
assays. To establish the role of the NS1 protein, we identified
the binding site of DDX21 on the NS1 protein and showed that
a recombinant virus that expresses a NS1 protein with amutated
DDX21 binding site does not counteract the inhibition of viral
gene expression mediated by endogenous DDX21. This result
established that the binding of endogenous DDX21 by the NS1
protein in infected cells suppresses DDX21 antiviral activity.
Further, this result also confirms that endogenous DDX21 is
responsible for the inhibition of viral gene expression. Additional
evidence for this mechanism might come from the identification
of the binding site of DDX21 on PB1, possibly enabling the gen-
eration of a recombinant virus that encodes PB1 with a mutated
DDX21 binding site. However, this is a formidable project that
may not provide clear results. First, it will be difficult to identify
the DDX21 binding site on the large (90 kDa) PB1 protein
because there is little or no structural information for PB1 (Boivin
et al., 2010; Resa-Infante et al., 2011). In addition, the identified
PB1 amino acids may have other required PB1 functions, e.g.,
viral RNA synthesis, binding to the PA and PB2 subunits of the
polymerase (Boivin et al., 2010; Resa-Infante et al., 2011).
Consequently, such a mutant PB1 protein may have several
defects that would make it difficult to identify a specific defect
caused by the lack of DDX21 binding. Future research will deter-Cell Host & Microbe 15, 484–mine whether it is feasible to generate a
recombinant virus that encodes a PB1
protein whose primary defect is in
DDX21 binding.
Our results thus provide strong support
for a mechanism by which influenza A
viral RNA and protein synthesis are regu-
lated in infected cells. At early times of
infection, DDX21 binds the small amount
of the PB1 protein that is initially synthe-sized and thus inhibits the association of PB1 with PA and PB2
to form a functional viral polymerase. However, the small
amounts of the PA and PB2 proteins that are initially synthesized
compete with DDX21 for binding PB1, albeit inefficiently, thereby
allowing a low level of synthesis of viral mRNAs and proteins to
occur. The NS1 protein that is synthesized binds DDX21 and
displaces the PB1 protein, suggesting that the binding sites of
NS1 and PB1 on DDX21 may be overlapping. The displacement
of PB1 from DDX21 leads to an increase in the formation of the
tripartite viral polymerase and hence to an increase in the synthe-
sis of vRNAs, viral mRNAs, and proteins. When sufficient
amounts of the NS1 protein are synthesized, essentially all of
the PB1 protein is dissociated from DDX21 and combines with
PA and PB2 to form the tripartite viral polymerase. Conse-
quently, the synthesis of viral RNAs and proteins is no longer
impeded. Because the amount of the NS1 protein that is synthe-
sized in infected cells greatly exceeds the amount of the PB1
protein that is synthesized, the NS1 protein would readily
outcompete the PB1 protein for binding DDX21. Thus, by virtue
of the binding of DDX21 by the NS1 protein, influenza A virus
transforms a host restriction factor into a host regulator of viral
gene expression.
The DDX21 helicase is a member of the family of DEXD RNA
helicases, which are comprised of a largely conserved helicase
core containing the DEXD sequence as well as flanking N-termi-
nal and C-terminal domains that are highly divergent and pre-
sumed to interact with various cellular proteins and/or RNAs
(Fuller-Pace, 2006). In fact, someDEXD helicases carry out func-
tions that do not require helicase activity, but rather aremediated
by their N-terminal and/or C-terminal domains. We show that the
inhibition of influenza viral RNA synthesis by DDX21 does not493, April 9, 2014 ª2014 Elsevier Inc. 491
Cell Host & Microbe
DDX21 Inhibits Influenza A Virus Replicationrequire its helicase activity and functions solely by binding PB1
and inhibiting its association with the PA and PB2 polymerase
subunits. Because neither the N-terminal domain, the core
helicase domain, nor the C-terminal domain of DDX21 was
sufficient for inhibiting viral RNA synthesis, the binding site for
PB1 may be comprised of more than one DDX21 domain.
DDX21 most likely binds PB1 in the cytoplasm, where PB1 is
probably free of the other polymerase subunits, albeit tran-
siently, before it forms a complex with PA that is imported into
the nucleus (Fodor and Smith, 2004). The PB1 protein in the
nucleus is predominately complexed with both PA and PB2 in
the tripartite viral polymerase and is probably not available for
binding to DDX21. Although DDX21 has been considered to be
a nucleolar protein, it does not function in ribosome biogenesis,
unlike many nucleolar proteins, indicating that DDX21 may
participate in extranucleolar functions (Tafforeau et al., 2013).
In fact, DDX21 has been reported to function in cytoplasmic
events, namely regulating the translation of the polycistronic
mRNA of Borna disease virus (Watanabe et al., 2009) and
sensing dsRNA in dendritic cells as part of a complex of three
helicases (Zhang et al., 2011). In addition, we have found that
whereas plasmid-expressed PB1 is localized in the cytoplasm,
as previously shown by others (Fodor and Smith, 2004), cotrans-
fection of PB1 and DDX21 plasmids results in a significant
portion of PB1 entering into the nucleus (Figure S4).
We showed that DDX21 binds to the RBD of NS1, specifically
to a region comprised of amino acids R37, R38, K41, and R44,
which also participates in binding dsRNA, a-importin, TRIM25,
and NP (Cheng et al., 2009; Chien et al., 2004; Gack et al.,
2009; Mele´n et al., 2007; Robb et al., 2011). This overlap of
NS1 sequences that mediate more than one function probably
reflects the fact that the NS1 protein in infected cells carries
out different functions at different sites in the cell. Because this
region of the NS1 RBD is crucial for multiple functions that are
required for virus infection, it should be an excellent target for
the development of influenza virus antivirals, particularly as
mutant viruses that express NS1 proteins in which alanine is
substituted for one or more of the amino acids in this region
are highly attenuated (Donelan et al., 2003; Gack et al., 2009;
Min and Krug, 2006). Consequently, small molecules that
strongly bind to this RBD region would be expected to be
extremely effective in inhibiting virus replication.
EXPERIMENTAL PROCEDURES
Cells and Viruses
HeLa, MDCK, HEL-299, 293T, and Calu3 cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% heat-inactivated
fetal bovine serum. WT Ud virus, Ud virus encoding NS1 and NS2/NEP
proteins with a N-terminal Flag tag (Zhao et al., 2010), Ud virus expressing a
mutant (R44A, K41A) NS1 protein, and WSN virus were generated by
plasmid-based reverse genetics as described previously (Takeda et al.,
2002; Twu et al., 2006). All eight genomic RNA segments of recombinant
viruses were sequenced. Virus stocks were grown in 10-day-old fertilized
eggs, and virus titers were determined by plaque assays in MDCK cells.
Purification of CPSF30-NS1 Complexes from Infected Cells
293T cells were transfected with a pcDNA3 plasmid encoding GST-CPSF30
using the Mirus TransIT-LTR Transfection Reagent, and 24 hr later were in-
fected with 2 pfu/cell of either WT Ud virus or the Ud virus expressing a
Flag-tagged NS1 protein. Cells were collected 12 hr after infection and disrup-492 Cell Host & Microbe 15, 484–493, April 9, 2014 ª2014 Elsevier Inted by suspension in a solution containing 50 mM Tris-HCl (pH 7.5), 150 mM
NaCl, 5 mM EDTA, 2.5 mM MgCl2, 1% NP40, 10% glycerol, 1 mM PMSF,
and 13 protease inhibitor (Roche), followed by passage through a 25G
needle. The extracts were affinity purified using glutathione Sepharose beads
as described previously. The eluate was then bound to agarose beads con-
taining theM2monoclonal Flag antibody, washed four times with a buffer con-
taining 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 0.25% NP40, and
Flag-containing protein complexes were eluted with 500 ng/ml of 33Flag
peptide. An aliquot of the eluate was analyzed by SDS-PAGE gel, which was
stained with Coomassie blue. Several molecular weight regions were cut out
and analyzed by mass spectroscopy (Harvard Taplin Mass Spectrometry
Facility). The proteins identified in the 90–110 kDa molecular weight region
are shown in Table S1.
DDX21 siRNAs
The siRNA duplexes against DDX21 were purchased from Invitrogen and
resuspended in diethyl pyrocarbonate-treated water to a final storage concen-
tration of 20 mM. The sequences of the two DDX21 siRNAs are as follows:
CCAGCGCUCCUUGAUCAACUCAAAU (DDX21-1) and AGGCCAGAAGCG
GAGUUUCAGUAAA (DDX21-2). The control siRNA, Stealth RNAi negative
control (medium G/C), was obtained from Invitrogen.
Preparation of Plasmids
The coding sequence of DDX21 was RT-PCR amplified from the total RNA of
293T cells using primers specific for the 50 and 30 ends of the DDX21 coding
sequence and containing SalI and BamH I restriction sites (shown in Supple-
mental Information). This DNA sequence was cloned into the expression
plasmid pCMVHF treated with SalI and BglII, thereby adding a Flag tag to
the 50 end of the DDX21 coding sequence. Standard oligonucleotide mutagen-
esis methods were used to change the DEAD sequence in DDX21 to AAAD.
The resulting DNA was sequenced to verify the substitution of the AAAD
sequence. To generate a plasmid expressing GST-tagged DDX21, the GST
sequence in the pGEX5X-3 plasmid was amplified using primers specific for
the 50 and 30 ends of GST and containing Hind III and KpnI restriction sites
(described in Supplemental Information), and it was cloned into pcDNA3 cut
with these two restriction enzymes. Then, a DDX21 DNA sequence containing
BamH I and Xho I restriction sites was generating using appropriate 50 and 30
primers (Supplemental Information), and this DNA was cloned into the GST-
containing pcDNA3 plasmid cut with BamH I and Xho I. To generate a plasmid
expressing C-terminal TAP-tagged PB1, the coding sequence of PB1 was
PCR amplified using 50- and 30-specific primers containing BamH I and Not I
restriction sites, and this DNA was cloned into pcDNA3-CTAP cut with these
two restriction enzymes. The NS1 sequences in the pcDNA-Ud NS1 and the
pCMV10-WSN NS1 plasmids contain a mutated 30 splice site (Alonso-Caplen
and Krug, 1991) to eliminate the production of the NS2/NEP mRNA and
protein. For bacteria expression, GST and the following NS1 coding
sequences were inserted into pGEX-6P1 vectors: NS1 (1–215), NS1
(74–215), WT NS1 (1–73), and NS1 (1–73) containing the indicated amino
acid substitutions. The resulting GST-tagged NS1 proteins, as well as the
GST tag alone, were expressed in Escherichia coli BL21.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.chom.2014.03.002.
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